Theravance Biopharma (TBPH) Projected to Post Quarterly Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) is expected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect Theravance Biopharma to post earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $9.31 on Monday. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $10.90. The firm has a market capitalization of $457.81 million, a PE ratio of -9.22 and a beta of 0.21. The business’s 50 day moving average price is $9.40 and its 200-day moving average price is $8.90.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by company insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.